Sign in
Taking people in South KoreaNo phase

Timing of Follow-Up Artery Treatment After a Major Heart Attack

Compares treating other narrowed heart arteries during hospital stay or after discharge.

Key facts

Who runs it
Chonnam National University Hospital
Where
Bucheon-si, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Gwangju, Gwangmyeong, Jeju City, Jeonju, Jinju, Pusan, Seoul, Suncheon, Suwon, and Yangsan, South KoreaSee the 30 sites
Trial code
Registry title
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Status
Recruiting
People taking part
1,252 people, planned
Started
21 Aug 2026
Expected to end
31 Jul 2035
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • In-hospital staged complete revascularization
  • Out-of-hospital staged complete revascularization
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a heart attack of the ST-elevation type (STEMI) who have narrowing in more than one heart artery. It tests when to open the other narrowed arteries after the main one is treated.

Age
19 years or older
Sex
All sexes can join
Disease stage
STEMI (ST-segment elevation heart attack) with primary stenting within 12 hours of symptoms, and at least 1 other artery, not the one that caused the heart attack, with diameter ≥ 2.5 mm and 50% stenosis by visual estimate
Earlier treatment
Primary PCI (stenting) within 12 h after symptom development. No clot-dissolving (fibrinolysis) treatment before admission. No past or planned bypass surgery (CABG).

Main reasons for not taking part

  • Cardiogenic shock at first presentation or after treatment of the infarct-related artery
  • Chronic total occlusion in another artery
  • Severe valvular heart disease
  • Pregnancy and breastfeeding
  • Life expectancy under 1 year

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age ≥19 years
  • ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB)
  • Primary PCI within 12 h after symptom development
  • At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation

Who cannot take part

  • Fibrinolysis therapy prior to admission
  • Thrombolysis in myocardial infarction flow at non-IRA ≤ 2
  • History of anaphylaxis to contrast agent
  • Severe valvular heart disease
  • History of coronary artery bypass grafting (CABG) or planned CABG
  • Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment
  • Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment
  • Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment
  • Chronic total occlusion in a non-IRA
  • Pregnancy and lactation
  • Life expectancy < 1 year
  • Severe asthma

Where in South Korea

  • Bucheon Sejong HospitalBucheon-si, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Gyeongsang National University Changwon hospitalChangwon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Samsung Changwon Medical CenterChangwon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Soon Chun Hyang University Hospital CheonanCheonan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Chungbuk National University HospitalCheongju-si, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Kangwon National University HospitalChuncheon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Daegu Catholic University Medical CenterDaegu, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Kyungpook National University HospitalDaegu, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Yeongnam University Medical CenterDaegu, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Chungnam National University HospitalDaejeon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Chonnam National University HospitalGwangju, South KoreaContact: Min Chul Kim, MD, PhDTaking people
  • Chosun University HospitalGwangju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Gwangju Veterans HospitalGwangju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Kwangju Christian HospitalGwangju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Jeju National University HospitalJeju City, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • jeonbuk National University HospitalJeonju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Presbyterian Medical CenterJeonju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Gyeongsang National University HospitalJinju, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Inje University Busan Paik HospitalPusan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Inje University Haeundae Paik HospitalPusan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Kosin University Gospel HospitalPusan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Pusan National University HospitalPusan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Koera University Guro HospitalSeoul, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Korea University Anam HospitalSeoul, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Yonsei University Health System - Gangnam Severance HospitalSeoul, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • St. Carollo General HospitalSuncheon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Ajou University HospitalSuwon, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting
  • Pusan National University Yangsan HospitalYangsan, South KoreaContact: Min Chul Kim, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.

The 2 groups in the trial

  • In-hospital staged complete revascularizationTreatment being tested

    In the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

  • Out-of-hospital staged complete revascularizationExisting treatment, for comparison

    In the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
OPtimal TIming of Staged Complete RevascularizatiON in ST-Segment Elevation Myocardial Infarction With Multivessel Disease: The OPTION-STEMI2 Trial
Plain-language title
Timing of Follow-Up Artery Treatment After a Major Heart AttackGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 October 2026